Materialise NV logo

Materialise NV (MTLS)

Market Closed
15 Aug, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
5. 17
-0.01
-0.19%
$
305.38M Market Cap
161.75 P/E Ratio
0% Div Yield
68,051 Volume
0.18 Eps
$ 5.18
Previous Close
Day Range
5.11 5.26
Year Range
3.93 9.69
Want to track MTLS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 66 days
Materialise: Automotive Weakness Is Undermining The Stock

Materialise: Automotive Weakness Is Undermining The Stock

Materialise's Q2 results were weak due to European automotive headwinds and macro uncertainty. Materialise's Medical segment continues to thrive, and its Software business is nearly done transitioning to a recurring revenue model. Medical segment strength justifies a higher valuation, but the Manufacturing business must stabilize before the stock can meaningfully re-rate.

Seekingalpha | 2 weeks ago
Materialise NV (MTLS) Q2 2025 Earnings Call Transcript

Materialise NV (MTLS) Q2 2025 Earnings Call Transcript

Materialise NV (NASDAQ:MTLS ) Q2 2025 Earnings Conference Call July 24, 2025 8:30 AM ET Company Participants Brigitte de Vet-Veithen - Chief Executive Officer Koen Berges - Chief Financial Officer Conference Call Participants Alexander Craeymeersch - Kepler Cheuvreux, Research Division Troy Donavon Jensen - Cantor Fitzgerald & Co., Research Division Harriet Fried - Unidentified Company Operator Good day, and thank you for standing by. Welcome to the Second Quarter 2025 Materialise NV Financial Results Conference Call.

Seekingalpha | 3 weeks ago
Materialise Q2 Preview: Anticipating Strong Medical Growth; Initiating With 'Buy'

Materialise Q2 Preview: Anticipating Strong Medical Growth; Initiating With 'Buy'

I rate Materialise a 'buy' with a fair value of $8.83, driven by its unique integrated 3D printing software and hardware solutions. Materialise's strategic focus on software and medical segments strengthens its competitive edge, with medical now 47% of revenue and growing double digits. Recurring software revenue exceeds 80% in its segment, supporting margin expansion, customer retention, and reducing business cyclicality.

Seekingalpha | 3 weeks ago
Materialise: Medical Segment Continues To Thrive

Materialise: Medical Segment Continues To Thrive

While Materialise's Q1 results were mixed they exceeded low investor expectations, with the company's Medical segment continuing to excel. Market conditions are likely to remain challenging, but lower energy costs and increased defense spending in Europe could help to offset this. Materialise's Medical segment alone more than justifies its current market capitalization.

Seekingalpha | 3 months ago
Materialise NV (MTLS) Q1 2025 Earnings Call Transcript

Materialise NV (MTLS) Q1 2025 Earnings Call Transcript

Materialise NV (NASDAQ:MTLS ) Q1 2025 Earnings Conference Call April 24, 2025 8:30 AM ET Company Participants Harriet Fried - Alliance Advisors, IR Brigitte de Vet - Chief Executive Officer Koen Berges - Chief Financial Officer Conference Call Participants Troy Jensen - Cantor Fitzgerald Operator Good day and thank you for standing by. Welcome to the First Quarter 2025 Materialise Financial Results Conference Call.

Seekingalpha | 3 months ago
Materialise: Manufacturing Headwinds Are A Distraction

Materialise: Manufacturing Headwinds Are A Distraction

Materialise: Manufacturing Headwinds Are A Distraction

Seekingalpha | 5 months ago
Materialise NV (MTLS) Q4 2024 Earnings Call Transcript

Materialise NV (MTLS) Q4 2024 Earnings Call Transcript

Materialise NV (NASDAQ:MTLS ) Q4 2024 Earnings Conference Call February 20, 2025 8:30 AM ET Company Participants Harriet Fried - Investor Relations Brigitte de Vet-Veithen - Chief Executive Officer Koen Berges - Chief Financial Officer Conference Call Participants Alexander Craeymeersch - Kepler Cheuvreux Troy Jensen - Cantor Fitzgerald Operator Ladies and gentlemen thank you for standing by. Welcome to the Fourth Quarter 2024 Materialise Financial Results Conference Call.

Seekingalpha | 5 months ago
Materialise (MTLS) Is a Great Choice for 'Trend' Investors, Here's Why

Materialise (MTLS) Is a Great Choice for 'Trend' Investors, Here's Why

Materialise (MTLS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zacks | 8 months ago
Should Value Investors Buy Materialise (MTLS) Stock?

Should Value Investors Buy Materialise (MTLS) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks | 8 months ago
Here's Why Momentum in Materialise (MTLS) Should Keep going

Here's Why Momentum in Materialise (MTLS) Should Keep going

Materialise (MTLS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks | 8 months ago
Materialise: Strong Q3 Results Despite Ongoing Market Headwinds

Materialise: Strong Q3 Results Despite Ongoing Market Headwinds

Materialise continues to grow on the back of its Medical segment, which is expanding at a rapid pace. Materialise's margins will continue to improve going forward, driven by a combination of revenue mix and economies of scale. The ACTech plant expansion will provide a material tailwind in 2025, although disruptions wrought by its startup are likely to negatively impact fourth quarter revenue.

Seekingalpha | 9 months ago
Are Investors Undervaluing Materialise (MTLS) Right Now?

Are Investors Undervaluing Materialise (MTLS) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks | 9 months ago
Loading...
Load More